Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.16
NVGN's Cash to Debt is ranked higher than
67% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. NVGN: 2.16 )
NVGN' s 10-Year Cash to Debt Range
Min: 2.16   Max: No Debt
Current: 2.16

Equity to Asset 0.70
NVGN's Equity to Asset is ranked higher than
74% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.60 vs. NVGN: 0.70 )
NVGN' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.86
Current: 0.7

0.33
0.86
F-Score: 1
Z-Score: -23.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -79.54
NVGN's Operating margin (%) is ranked lower than
54% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.34 vs. NVGN: -79.54 )
NVGN' s 10-Year Operating margin (%) Range
Min: -882.08   Max: -31.89
Current: -79.54

-882.08
-31.89
Net-margin (%) -59.60
NVGN's Net-margin (%) is ranked lower than
53% of the 713 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NVGN: -59.60 )
NVGN' s 10-Year Net-margin (%) Range
Min: -689.28   Max: 55.14
Current: -59.6

-689.28
55.14
ROE (%) -25.51
NVGN's ROE (%) is ranked lower than
52% of the 716 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. NVGN: -25.51 )
NVGN' s 10-Year ROE (%) Range
Min: -153.65   Max: 37.66
Current: -25.51

-153.65
37.66
ROA (%) -17.93
NVGN's ROA (%) is ranked lower than
51% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.95 vs. NVGN: -17.93 )
NVGN' s 10-Year ROA (%) Range
Min: -64   Max: 14.57
Current: -17.93

-64
14.57
ROC (Joel Greenblatt) (%) -11466.67
NVGN's ROC (Joel Greenblatt) (%) is ranked lower than
59% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.63 vs. NVGN: -11466.67 )
NVGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16308.96   Max: -57.68
Current: -11466.67

-16308.96
-57.68
Revenue Growth (%) 809.40
NVGN's Revenue Growth (%) is ranked higher than
100% of the 549 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NVGN: 809.40 )
NVGN' s 10-Year Revenue Growth (%) Range
Min: -51   Max: 809.4
Current: 809.4

-51
809.4
EBITDA Growth (%) 292.10
NVGN's EBITDA Growth (%) is ranked higher than
100% of the 504 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.00 vs. NVGN: 292.10 )
NVGN' s 10-Year EBITDA Growth (%) Range
Min: -23.9   Max: 292.1
Current: 292.1

-23.9
292.1
EPS Growth (%) 116.50
NVGN's EPS Growth (%) is ranked higher than
98% of the 506 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. NVGN: 116.50 )
NVGN' s 10-Year EPS Growth (%) Range
Min: -27.5   Max: 116.5
Current: 116.5

-27.5
116.5
» NVGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

NVGN Guru Trades in Q4 2012

Jim Simons 48,940 sh (+4.93%)
Ronald Muhlenkamp 18,184 sh (-49.15%)
» More
Q1 2013

NVGN Guru Trades in Q1 2013

Ronald Muhlenkamp Sold Out
Jim Simons 44,940 sh (-8.17%)
» More
Q2 2013

NVGN Guru Trades in Q2 2013

Jim Simons 15,240 sh (-66.09%)
» More
Q3 2013

NVGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2013-03-31 Sold Out 0.03%$1.84 - $9.05 $ 3.67-4%0
Ronald Muhlenkamp 2012-12-31 Reduce -49.15%0.01%$1.5 - $10.24 $ 3.67-26%18184
Ronald Muhlenkamp 2012-06-30 New Buy0.02%$1.95 - $2.5 $ 3.6762%35757
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.50
NVGN's P/B is ranked lower than
59% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.84 vs. NVGN: 5.50 )
NVGN' s 10-Year P/B Range
Min: 0.95   Max: 19.26
Current: 5.5

0.95
19.26
P/S 2.90
NVGN's P/S is ranked higher than
61% of the 717 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.95 vs. NVGN: 2.90 )
NVGN' s 10-Year P/S Range
Min: 0   Max: 37.69
Current: 2.9

0
37.69
EV-to-EBIT 22.20
NVGN's EV-to-EBIT is ranked higher than
60% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.45 vs. NVGN: 22.20 )
NVGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 22.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 16.70
NVGN's Price/Net Cash is ranked higher than
54% of the 219 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.70 vs. NVGN: 16.70 )
NVGN' s 10-Year Price/Net Cash Range
Min: 2.36   Max: 23.3
Current: 16.7

2.36
23.3
Price/Net Current Asset Value 16.00
NVGN's Price/Net Current Asset Value is ranked lower than
51% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.80 vs. NVGN: 16.00 )
NVGN' s 10-Year Price/Net Current Asset Value Range
Min: 1.83   Max: 19.5
Current: 16

1.83
19.5
Price/Tangible Book 14.70
NVGN's Price/Tangible Book is ranked lower than
75% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.10 vs. NVGN: 14.70 )
NVGN' s 10-Year Price/Tangible Book Range
Min: 1.5   Max: 19.5
Current: 14.7

1.5
19.5
Forward Rate of Return (Yacktman) -13578.93
NVGN's Forward Rate of Return (Yacktman) is ranked lower than
59% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. NVGN: -13578.93 )
NVGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -13578.93

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:NRT.Australia, NV9.Germany, NV9B.Germany
Novogen Ltd. research, develops & markets pharmaceutical products. It offers its products therapeutic area cancer, heart disease, inflammatory bowel disease & other chronic inflammatory diseases & also provides health supplements.
» More Articles for NAS:NVGN

Headlines

Articles On GuruFocus.com
comment on NVGN Mar 06 2013 

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide